[go: up one dir, main page]

SG10201906912VA - Glucagon derivatives - Google Patents

Glucagon derivatives

Info

Publication number
SG10201906912VA
SG10201906912VA SG10201906912VA SG10201906912VA SG10201906912VA SG 10201906912V A SG10201906912V A SG 10201906912VA SG 10201906912V A SG10201906912V A SG 10201906912VA SG 10201906912V A SG10201906912V A SG 10201906912VA SG 10201906912V A SG10201906912V A SG 10201906912VA
Authority
SG
Singapore
Prior art keywords
glucagon
peptide
present
treating obesity
receptors
Prior art date
Application number
SG10201906912VA
Inventor
Sung Youb Jung
Young Jin Park
Jong Suk Lee
Jae Hyuk Choi
Chang Ki Lim
Se Chang Kwon
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of SG10201906912VA publication Critical patent/SG10201906912VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

GLUCAGON DERIVATIVES The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity. NO FIGURE
SG10201906912VA 2014-12-30 2015-12-30 Glucagon derivatives SG10201906912VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140193691A KR102418477B1 (en) 2014-12-30 2014-12-30 Gluagon Derivatives

Publications (1)

Publication Number Publication Date
SG10201906912VA true SG10201906912VA (en) 2019-09-27

Family

ID=56284668

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201906912VA SG10201906912VA (en) 2014-12-30 2015-12-30 Glucagon derivatives
SG11201705130XA SG11201705130XA (en) 2014-12-30 2015-12-30 Glucagon derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201705130XA SG11201705130XA (en) 2014-12-30 2015-12-30 Glucagon derivatives

Country Status (18)

Country Link
US (3) US10513550B2 (en)
EP (1) EP3240802B1 (en)
JP (1) JP6758297B2 (en)
KR (1) KR102418477B1 (en)
CN (1) CN107250155B (en)
AR (1) AR103323A1 (en)
AU (1) AU2015372767B2 (en)
BR (1) BR112017013845A2 (en)
CA (1) CA2972001C (en)
EA (1) EA036479B1 (en)
IL (1) IL253001B (en)
MX (1) MX389593B (en)
PH (1) PH12017501205A1 (en)
SG (2) SG10201906912VA (en)
TW (1) TWI696631B (en)
UA (1) UA122967C2 (en)
WO (1) WO2016108617A1 (en)
ZA (1) ZA201704328B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3575314B1 (en) * 2014-12-30 2024-02-14 Hanmi Pharm. Co., Ltd. Glucagon derivative
EP3322437B1 (en) 2015-06-30 2024-01-17 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
TWI622596B (en) 2015-10-26 2018-05-01 美國禮來大藥廠 Glucagon receptor agonist
CN116059389A (en) 2015-12-31 2023-05-05 韩美药品株式会社 Long-acting conjugates of glucagon/GLP-1/GIP receptor triple agonists
EP4572782A1 (en) 2022-08-18 2025-06-25 Boehringer Ingelheim International GmbH Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1060746A4 (en) 1998-03-06 2002-06-19 Chugai Pharmaceutical Co Ltd Protein-free preparations
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
KR101135244B1 (en) 2007-11-29 2012-04-24 한미사이언스 주식회사 A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US20090238838A1 (en) 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
DK1682583T3 (en) 2003-11-13 2012-05-07 Hanmi Holdings Co Ltd Protein complex formation using immunoglobulin fragment and method of preparation thereof
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR20070094909A (en) 2004-12-02 2007-09-27 도만티스 리미티드 Antibodies with Serum Albumin and Bispecific Domains Targeting JP-1 or JP
EP2390264A1 (en) 2005-02-11 2011-11-30 Amylin Pharmaceuticals Inc. GIP analog and hybrid polypeptides with selectable propperties
KR100754667B1 (en) 2005-04-08 2007-09-03 한미약품 주식회사 Immunoglobulin Fc Fragments Modified with Non-Peptide Polymers and Pharmaceutical Compositions Comprising the Same
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
SI1891105T1 (en) 2005-06-13 2012-07-31 Imp Innovations Ltd Oxyntomodulin analogues and their effects on feeding behaviour
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
WO2007030375A2 (en) 2005-09-08 2007-03-15 Children's Hospital Medical Center Lysosomal acid lipase therapy for nafld and related diseases
WO2007100535A2 (en) * 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
KR100880509B1 (en) 2006-10-16 2009-01-28 한미약품 주식회사 Novel vectors, expression cell lines, and methods for producing recombinant proteins using the same for mass production of recombinant proteins
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
GB0624868D0 (en) 2006-12-13 2007-01-24 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (en) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd Insulin secretory peptide drug conjugates using carrier substances
KR20090119876A (en) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon / LPL-1 Receptor Co-Analyst
US20100196405A1 (en) 2007-07-10 2010-08-05 Kingman Ng GLP-1 Fc FUSION PROTEIN FORMULATION
CN103416421B (en) 2007-07-27 2016-07-27 拜尔农作物科学股份公司 Ternary active compound combinations
EP2187525B1 (en) 2007-08-07 2014-03-12 Fujitsu Limited Error detection device, and error correction/error detection decoding device and method
AU2008306141A1 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Thyrotropin releasing hormone for therapeutic applications
WO2009058734A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
EP2214700A4 (en) 2007-11-02 2012-08-22 Janssen Biotech Inc Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
JP5775450B2 (en) 2008-06-17 2015-09-09 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon / GLP-1 receptor co-agonist
JP5753779B2 (en) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon analogs with improved solubility and stability in buffers at physiological pH
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US20110171312A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
FR2936441B1 (en) 2008-09-26 2012-12-07 Rhodia Operations COMPOSITE POLYAMIDE ARTICLE
DK2370461T3 (en) * 2008-12-15 2013-12-16 Zealand Pharma As glucagon
WO2010071807A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
EP3178835B1 (en) 2009-02-03 2019-04-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
MY150536A (en) 2009-03-20 2014-01-30 Hanmi Science Co Ltd Method for preparing a site-specific physiologically active polypeptide conjugate
US8734796B2 (en) 2009-03-20 2014-05-27 Amgen Inc. Carrier immunoglobulins
BRPI1014508A2 (en) 2009-06-16 2016-04-05 Univ Indiana Res & Tech Corp glucagon peptide analogs, dimer of two glucagon peptides, pharmaceutical composition derived from them and methods for their use "
JP6054742B2 (en) * 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ Acylated glucagon analogues
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
WO2011075393A2 (en) * 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
AR079345A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli OXINTOMODULINE PEPTIDAL ANALOG
AR079344A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY
EA026384B1 (en) * 2010-01-20 2017-04-28 Зилэнд Фарма А/С Treatment of cardiac conditions
BR112012018585A2 (en) 2010-01-27 2017-01-10 Univ Indiana Res & Tech Corp antagonist-gon agonist glucagon compositions and compositions for the treatment of metabolic disorders and obesity
AU2011231503C1 (en) * 2010-03-26 2016-03-03 Novo Nordisk A/S Novel glucagon analogues
AR081066A1 (en) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd INSULIN CONJUGATE WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
KR20130102470A (en) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Amide based glucagon superfamily peptide prodrugs
KR101337797B1 (en) 2010-07-14 2013-12-06 한미사이언스 주식회사 A liquid formulation of long acting human growth hormone conjugate
KR101382593B1 (en) 2010-07-21 2014-04-10 한미사이언스 주식회사 Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
JP5282146B2 (en) 2010-09-06 2013-09-04 パナソニック株式会社 Display device and control method thereof
CN101974077A (en) 2010-09-15 2011-02-16 南京瑞年天平医药科技有限公司 Novel polypeptide compound
KR101303388B1 (en) 2010-10-26 2013-09-03 한미사이언스 주식회사 Liquid formulations of long acting interferon alpha conjugate
KR101767570B1 (en) 2010-10-26 2017-08-14 한미사이언스 주식회사 A long-lasting conjugate of An anti-obesity peptide derivative complex
CN102010473A (en) 2010-11-10 2011-04-13 曹鹏 Recombinant oxyntomodulin (OXM) fusion protein, and preparation and application thereof
AR084558A1 (en) 2010-12-22 2013-05-22 Marcadia Biotech METHODS TO TREAT METABOLIC DISORDERS AND OBESITY WITH ACTIVE GLUCAGON-BASED PEPTIDES FOR THE GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP) / PEPTIDO-1 SIMILAR TO GLUCAGON (GLP-1)
JP6118500B2 (en) 2011-02-28 2017-04-19 ローム アンド ハース エレクトロニック マテリアルズ エルエルシーＲｏｈｍ ａｎｄ Ｈａａｓ Ｅｌｅｃｔｒｏｎｉｃ Ｍａｔｅｒｉａｌｓ ＬＬＣ Photoresist composition and method for forming photolithography pattern
KR101161526B1 (en) 2011-05-16 2012-07-02 숭실대학교산학협력단 Catalyst electrode of core/shell nanostructure supports and method of it for fuel cell
ES2692187T3 (en) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. New oxintomodulin derivatives and pharmaceutical composition for the treatment of obesity comprising it
PH12013502517A1 (en) 2011-06-17 2014-01-20 Hanmi Science Co Ltd A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
US8729017B2 (en) 2011-06-22 2014-05-20 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
KR101665009B1 (en) 2012-03-09 2016-10-11 한미사이언스 주식회사 Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
MX2014012625A (en) 2012-04-19 2015-05-15 Opko Biolog Ltd Long-acting oxyntomodulin variants and methods of producing same.
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
KR101373563B1 (en) 2012-07-25 2014-03-12 전북대학교산학협력단 Method of derivation for hemodynamics and MR-signal intensity gradient(or shear rate) using Time-Of-Flight - Magnetic Resonance Angiography
KR101968344B1 (en) 2012-07-25 2019-04-12 한미약품 주식회사 A composition for treating hyperlipidemia comprising oxyntomodulin analog
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
KR101993393B1 (en) 2012-11-06 2019-10-01 한미약품 주식회사 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
ES2748158T3 (en) 2012-11-06 2020-03-13 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising oxyntomodulin and an immunoglobulin fragment
PL2986313T3 (en) * 2013-04-18 2019-12-31 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
JP6137046B2 (en) 2014-05-09 2017-05-31 信越化学工業株式会社 Monomer, polymer compound, resist material and pattern forming method
TWI772252B (en) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
WO2019171352A2 (en) 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity

Also Published As

Publication number Publication date
CA2972001C (en) 2024-07-02
AU2015372767A1 (en) 2017-07-13
US12018060B2 (en) 2024-06-25
UA122967C2 (en) 2021-01-27
MX389593B (en) 2025-03-20
IL253001B (en) 2022-04-01
MX2017008715A (en) 2017-11-17
CN107250155B (en) 2021-08-10
US20220025012A1 (en) 2022-01-27
EP3240802A1 (en) 2017-11-08
KR102418477B1 (en) 2022-07-08
JP2018505153A (en) 2018-02-22
EA036479B1 (en) 2020-11-16
EA201791498A1 (en) 2017-10-31
IL253001A0 (en) 2017-08-31
US20200140515A1 (en) 2020-05-07
US10513550B2 (en) 2019-12-24
TWI696631B (en) 2020-06-21
SG11201705130XA (en) 2017-07-28
TW201632546A (en) 2016-09-16
PH12017501205A1 (en) 2017-10-18
US11254724B2 (en) 2022-02-22
AU2015372767B2 (en) 2020-07-16
NZ733649A (en) 2024-07-26
KR20160082026A (en) 2016-07-08
JP6758297B2 (en) 2020-09-23
NZ771617A (en) 2024-09-27
BR112017013845A2 (en) 2018-01-02
CA2972001A1 (en) 2016-07-07
US20180002395A1 (en) 2018-01-04
AR103323A1 (en) 2017-05-03
ZA201704328B (en) 2021-01-27
EP3240802A4 (en) 2018-10-10
WO2016108617A1 (en) 2016-07-07
CN107250155A (en) 2017-10-13
HK1246323A1 (en) 2018-09-07
EP3240802B1 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
PH12018502742A1 (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
ZA202007143B (en) Pyridone derivative, composition thereof and application thereof as anti-influenza drug
PH12017502393A1 (en) Glucagon derivative and a composition comprising a long acting conjugate of the same
TN2018000228A1 (en) Triple activator activating glucagon, glp-1 and gip receptor
UA118558C2 (en) Peptide compound
SG11202000940XA (en) Glp-1 compositions and uses thereof
TW201613633A (en) Exendin-4 derivatives as selective glucagon receptor agonists
MX2018015656A (en) Heterocyclic compounds as antibacterials.
MX2016016593A (en) Novel aminoalkyl benzothiazepine derivative and use thereof.
MX2020003217A (en) Long-acting co-agonists of the glucagon and glp-1 receptors.
MX2018015657A (en) Heterocyclic compounds as antibacte rials.
JO3564B1 (en) Peptides and formulations to treat joint damage
EP3575314A3 (en) Glucagon derivatives
PH12017501205A1 (en) Glucagon derivatives
NZ733670A (en) Insulin glargine/lixisenatide fixed ratio formulation
MX376200B (en) NASAL POWDER FORMULATION FOR THE TREATMENT OF HYPOGLYCEMIA.
ZA202507394B (en) Semaglutide in cardiovascular conditions
MX2020006596A (en) Hydroxyisoxazolines and derivatives thereof.
MX2017005249A (en) Compounds for use in anthelminthic treatment.
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2017001047A (en) Compounds for use in anthelminthic treatment.
PH12018500118A1 (en) Antitussive compositions and methods
AR107282A1 (en) TRIPLE AGONIST THAT HAS ACTIVITY FOR A GLUCAGON RECEIVER, A GLUCAGON PEPTIDE 1 RECEIVER (GLP-1) AND A GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP)
CR20190161A (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
UA93017U (en) "nanovulin-bpx" medication